Evidence map›Paper›PMID 39149088›Full record

ArticleHeliyon2024

Creating the vaccination improvement potential index.

Francisco Rios Casas, Jacob Armitage, Joanna Yuan, Shan Liu, Ali H Mokdad

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Francisco Rios CasasPopulation Health Initiative, Hans Rosling Center for Population Health, University of Washington, Box 351622, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Jacob ArmitagePopulation Health Initiative, Hans Rosling Center for Population Health, University of Washington, Box 351622, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Joanna YuanPopulation Health Initiative, Hans Rosling Center for Population Health, University of Washington, Box 351622, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Shan LiuDepartment of Industrial & Systems Engineering University of Washington, Box 352650, Seattle, WA, 98195, USA.
Ali H MokdadInstitute for Health Metrics and Evaluations, Department of Health Metrics Sciences, Hans Rosling Center for Population Health, University of Washington Box 351615, Seattle, WA, 98195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Numerous social and behavioral factors have been implicated in vaccination coverage. There is no single measure that describes a country's ability to improve or maintain its immunization coverage. Methods: We estimated the "Vaccination Improvement Potential" (VIP) by taking the geometric mean of 13 different indicators on health financing, vaccine confidence, and socio-demographics for more than 200 countries across 30 years. Potential VIP Index values range from 0 to 1, with a higher score indicating greater potential to improve or maintain high vaccination rates. Findings: In 1990, the mean VIP score was 0.49 (range = 0.13 to 0.86). In 2019, the mean score was 0.59 (range = 0.25 to 0.84). Consistent high performers included countries in Western Europe and high-income North America and East Asia. Important differences in subcomponents of the index drove major trends including vaccine hesitancy in Western Europe and Asia as well as lower levels of per capita health spending and development assistance in sub-Saharan Africa. Interpretation: The VIP Index is a first-of-its-kind tool for understanding the capacity that exists in a country to realize improved immunization rates. It is a new resource that can guide researchers, policymakers, and health officials to more effectively deploy resources to realize improvements in vaccination coverage, assess the impact of those improvements, and identify countries that might require additional support to improve vaccine coverage. Funding: Merck Sharp & Dohme Corp.

Identifiers

PMID39149088
PMCPMC11325368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.